AbbVie Inc (NYSE:ABBV) has been downgraded to Neutral in a statement by Citigroup Inc. earlier today.
- Updated: November 28, 2016
Having a price of $60.51, AbbVie Inc (NYSE:ABBV) traded 0.55% higher on the day. The last stock close price is down -3.54% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. The company has recorded a 50-day moving average of $60.51 and a 200-day moving average of $62.73. 2,942,309 shares of ABBV traded, down from an average trading volume of 7,255,480
Citigroup Inc. has downgraded AbbVie Inc (NYSE:ABBV) to Neutral in a statement released on Monday November 28, 2016.
Previously on 11/28/2016, Vetr Inc. reported about AbbVie Inc (NYSE:ABBV) raised the target price from $0.00 to $67.75. At the time, this indicated a possible upside of 0.12%.
AbbVie Inc has a price-earnings ratio of 16.36 with a one year low of $50.71 and a 52 week high of $68.12 The company’s market cap is currently $0.
Also covering AbbVie Inc's price target, a total of 18 equity analysts have released a ratings update on ABBV. The one year target is $70.22 with four analysts rating the company a strong buy, ten firms rating the stock a buy, 5 firms rating the stock a hold, 1 brokerage rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About AbbVie Inc (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.